208 related articles for article (PubMed ID: 19582512)
1. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
[TBL] [Abstract][Full Text] [Related]
4. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
[TBL] [Abstract][Full Text] [Related]
7. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.
Herman JM; Swartz MJ; Hsu CC; Winter J; Pawlik TM; Sugar E; Robinson R; Laheru DA; Jaffee E; Hruban RH; Campbell KA; Wolfgang CL; Asrari F; Donehower R; Hidalgo M; Diaz LA; Yeo C; Cameron JL; Schulick RD; Abrams R
J Clin Oncol; 2008 Jul; 26(21):3503-10. PubMed ID: 18640931
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Hsu CC; Herman JM; Corsini MM; Winter JM; Callister MD; Haddock MG; Cameron JL; Pawlik TM; Schulick RD; Wolfgang CL; Laheru DA; Farnell MB; Swartz MJ; Gunderson LL; Miller RC
Ann Surg Oncol; 2010 Apr; 17(4):981-90. PubMed ID: 20087786
[TBL] [Abstract][Full Text] [Related]
9. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
Krishnan S; Rana V; Evans DB; Varadhachary G; Das P; Bhatia S; Delclos ME; Janjan NA; Wolff RA; Crane CH; Pisters PW
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):735-43. PubMed ID: 17980502
[TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
Horowitz DP; Hsu CC; Wang J; Makary MA; Winter JM; Robinson R; Schulick RD; Cameron JL; Pawlik TM; Herman JM
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1391-7. PubMed ID: 20643511
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
Corsini MM; Miller RC; Haddock MG; Donohue JH; Farnell MB; Nagorney DM; Jatoi A; McWilliams RR; Kim GP; Bhatia S; Iott MJ; Gunderson LL
J Clin Oncol; 2008 Jul; 26(21):3511-6. PubMed ID: 18640932
[TBL] [Abstract][Full Text] [Related]
13. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
[TBL] [Abstract][Full Text] [Related]
14. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
[TBL] [Abstract][Full Text] [Related]
17. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
Varadhachary GR; Wolff RA; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Abdalla E; Wang H; Staerkel GA; Lee JH; Ross WA; Tamm EP; Bhosale PR; Krishnan S; Das P; Ho L; Xiong H; Abbruzzese JL; Evans DB
J Clin Oncol; 2008 Jul; 26(21):3487-95. PubMed ID: 18640929
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
